scispace - formally typeset
F

Fang-Ming Chen

Researcher at Kaohsiung Medical University

Publications -  90
Citations -  1777

Fang-Ming Chen is an academic researcher from Kaohsiung Medical University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 22, co-authored 87 publications receiving 1533 citations. Previous affiliations of Fang-Ming Chen include Kaohsiung Medical University Chung-Ho Memorial Hospital.

Papers
More filters
Journal ArticleDOI

Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.

TL;DR: The identification of circulating tumor DNA using the molecular detection of APC, K-ras, and p53 gene mutations is a potential tool for early detection of postoperative recurrence/metastases in patients with colorectal cancer after tumor resection.
Journal ArticleDOI

Combination of Multiple mRNA Markers (PTTG1, Survivin, UbcH10 and TK1) in the Diagnosis of Taiwanese Patients with Breast Cancer by Membrane Array

TL;DR: It was demonstrated that the multimarker membrane array method could detect CTCs in the circulation of breast cancer patients with considerably high sensitivity and specificity.
Journal ArticleDOI

Randomized controlled trial of LigaSure with submucosal dissection versus Ferguson hemorrhoidectomy for prolapsed hemorrhoids.

TL;DR: LigaSure hemorrhoidectomy with submucosal dissection is a safe, effective procedure for grade III and IV hemorrhoids and patients derive greater short-term benefits: reduced intraoperative blood loss, operating time, and postoperative pain as well as earlier resumption of work or normal activity.
Journal ArticleDOI

APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.

TL;DR: The findings suggest that serum molecular markers are potentially useful in the determination of colorectal cancer patients harboring gene mutations at high risk of metastasis and Serial analysis is warranted in order to assess their long-term prognostic significance and the therapeutic implications.
Journal ArticleDOI

Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes.

TL;DR: Pre-αPEG may have potential as a marker to aid development of personalized therapy using LipoDox and achieve optimal therapeutic efficacy and biodistribution results suggested that pre- αPEG Ab can significantly reduce tumor accumulation and accelerate blood clearance from the spleen.